Checkpoint Therapeutics (NASDAQ:CKPT) Now Covered by D. Boral Capital

Stock analysts at D. Boral Capital initiated coverage on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 184.81% from the company’s previous close.

A number of other brokerages also recently weighed in on CKPT. Lake Street Capital raised their price objective on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research note on Monday, December 16th.

Checkpoint Therapeutics Stock Performance

Shares of CKPT stock opened at $3.16 on Monday. The stock’s 50 day simple moving average is $3.64 and its 200 day simple moving average is $2.87. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The company has a market capitalization of $154.31 million, a price-to-earnings ratio of -1.72 and a beta of 1.36.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, analysts forecast that Checkpoint Therapeutics will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32. Following the transaction, the chief financial officer now directly owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. The trade was a 20.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO James F. Oliviero III sold 220,230 shares of Checkpoint Therapeutics stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total value of $744,377.40. Following the sale, the chief executive officer now directly owns 3,194,583 shares in the company, valued at $10,797,690.54. The trade was a 6.45 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.10% of the company’s stock.

Institutional Trading of Checkpoint Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after buying an additional 124,787 shares in the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in Checkpoint Therapeutics by 366.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after buying an additional 180,050 shares in the last quarter. PVG Asset Management Corp boosted its stake in Checkpoint Therapeutics by 9.2% in the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after buying an additional 12,676 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Checkpoint Therapeutics by 160.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares in the last quarter. Finally, State Street Corp boosted its stake in Checkpoint Therapeutics by 32.2% in the third quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after purchasing an additional 23,000 shares in the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.